Teleflex (TFX) Competitors

Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Which has stronger valuation & earnings, TFX or PODD?

Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$2.79B	3.43	$363.14M	$7.79	26.19
Insulet	$1.31B	8.33	$4.60M	$0.89	174.94

Which has more risk and volatility, TFX or PODD?

Teleflex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Does the media favor TFX or PODD?

In the previous week, Teleflex had 4 more articles in the media than Insulet. MarketBeat recorded 7 mentions for Teleflex and 3 mentions for Insulet. Insulet's average media sentiment score of 1.05 beat Teleflex's score of 0.66 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend TFX or PODD?

Teleflex currently has a consensus target price of $268.92, suggesting a potential upside of 31.81%. Insulet has a consensus target price of $281.93, suggesting a potential upside of 81.07%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.42
Insulet	0 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.56

Is TFX or PODD more profitable?

Teleflex has a net margin of 12.71% compared to Insulet's net margin of 4.29%. Insulet's return on equity of 22.42% beat Teleflex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	12.71%	15.48%	9.14%
Insulet	4.29%	22.42%	4.83%

Does the MarketBeat Community prefer TFX or PODD?

Insulet received 192 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.94% of users gave Insulet an outperform vote while only 59.65% of users gave Teleflex an outperform vote.

Company	Underperform	Outperform
Teleflex	Outperform Votes 507 59.65%	Underperform Votes 343 40.35%
Insulet	Outperform Votes 699 65.94%	Underperform Votes 361 34.06%

Do institutionals & insiders have more ownership in TFX or PODD?

97.2% of Teleflex shares are owned by institutional investors. 1.4% of Teleflex shares are owned by company insiders. Comparatively, 0.9% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Teleflex and Insulet tied by winning 9 of the 18 factors compared between the two stocks.